Travere Therapeutics, Inc. provides financial guidance for the fourth quarter and for the fiscal year 2022. The Company expects net product sales for the fourth quarter of 2022 to be approximately $52 million.
For the fiscal year 2022, the Company expects total revenue of $212 million, inclusive of approximately $201 million in net product sales and approximately $11 million in licensing and collaboration revenue.